Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.

Centene Could Decline Further as Broader Market Weakens

Let's check the charts of the health plan provider.

Jim Cramer: I Don't See a Way Out of the Spiral Down Until We Have a Vaccine

We are back to square one except for one positive and one negative.

A 4.5% Dividend Stock Trading at a Healthy Discount

The stock is simply too cheap, given its strong results to begin 2020, and a highly profitable business model that generates huge amounts of cash flow.

Does Abbott Labs Still Pass My Test After Earnings?

Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.

Analyst Bets Compass' 'Magic Mushroom' Approach Is on the Button

Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.

Jim Cramer: Here's How We're Going to Beat Covid-19

Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.

MultiPlan Can Plod Along With Slow, but Consistent Growth

The decline of the healthcare firm's stock offers the opportunity to sell out-of-the-money puts for an attractive premium.

Walgreens Does Not Show a Bullish Pattern Ahead of Earnings

The company is set to report earnings on Thursday.

How to Play Social Capital III's Purchase of Clover Health

It's not the merits of the deal from a long-term perspective I want to trade. It's the beat down of the stock from above $13 to under $11.